Drug intelligence / Profile preview

SOD2 mRNA

Development stage
Preclinical
Lead developer
Altamira Therapeutics
Modality
mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

SOD2 mRNA refers to messenger RNA encoding the human mitochondrial enzyme superoxide dismutase 2 (SOD2), also known as manganese-dependent superoxide dismutase (MnSOD). This enzyme plays a critical role in cellular defense against oxidative stress by catalyzing the conversion of toxic superoxide radicals into hydrogen peroxide and oxygen within mitochondria. Therapeutically, exogenous delivery of SOD2 mRNA using nanoparticle-based systems has been shown in preclinical models to increase SOD2 protein expression, reduce reactive oxygen species (ROS), and mitigate disease processes driven by oxidative stress. Notably, systemic administration of SOD2 mRNA via peptide-based nanoparticles has demonstrated efficacy in reducing aortic dilation and improving survival in mouse models of abdominal aortic aneurysm (AAA) by modulating oxidative damage and inflammation. The approach is being explored for cardiovascular diseases such as AAA and potentially other inflammatory or degenerative conditions where ROS is implicated[1][2].

Other names
superoxide dismutase 2 mRNAMnSOD mRNA
02

Targets

Misfolded SOD1

Beyond the preview

Go deeper on SOD2 mRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOD2 mRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call